ALLO — Allogene Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737287 ·
Last close
$2.03
Market Cap
$701.35M
52W High
$2.32
52W Low
$1.61
ADV30
5,665,704
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -46,092,000 | -42,607,000 | 395,958,000 | 30,309,000 | 117,083,000 |
| Dec 2025 | 0 | — | -42,404,000 | -38,810,000 | 415,905,000 | 51,688,000 | 123,363,000 |
| Sep 2025 | 0 | — | -44,901,000 | -41,400,000 | 439,771,000 | 37,815,000 | 124,442,000 |
| Jun 2025 | 0 | — | -54,437,000 | -50,943,000 | 470,593,000 | 52,332,000 | 126,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,230,000
Investing CF
$59,795,000
Financing CF
$37,289,000
CapEx
$-395,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.77
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,053,316,000
Inventory
—
Receivables
—
ST Investments
$236,577,000
EBIT TTM
$-172,535,000
Pretax Income TTM
$-173,760,000
Interest Exp TTM
$1,225,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,640,000
EBITDA
$-168,648,992
Free Cash Flow
$-63,461,624
Enterprise Value
$468,480,928
Total Cash
$332,604,000
Total Debt
$79,009,000
Shares Out
345,490,881
Trailing EPS
$-0.66
Book Value
$1.26
ROE
-42.4%
ROA
-22.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -206,933,000 | -190,886,000 | 415,905,000 | 123,363,000 | — | -149,246,000 |
| Dec 2024 | 22,000 | -257,482,000 | -257,590,000 | 548,710,000 | 126,531,000 | — | -200,300,000 |
| Dec 2023 | 95,000 | -314,492,000 | -327,265,000 | 642,837,000 | 130,604,000 | — | -237,733,000 |
| Dec 2022 | 156,000 | -335,536,000 | -340,414,000 | 821,579,000 | 154,697,000 | — | -220,519,000 |
TTM Snapshot
Revenues TTM
$120,000
NetIncome TTM
$-289,979,000
OpCashFlow TTM
$0
Assets (Latest)
$548,710,000
Forward EPS
$-0.70
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $2.03 · call volume: 268 · put volume: 650
Expected Move to 2026-09-18:
±$0.45
(22.17%) —
implied range
$1.58 –
$2.48
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc. | $712.97M | $36.47 | — |
| VALN | Valneva SE | $640.06M | $6.75 | — |
| AGMB | Agomab Therapeutics NV | $631.36M | $12.82 | — |
| AUTL | Autolus Therapeutics plc | $622.82M | $2.34 | — |
| EIKN | Eikon Therapeutics, Inc. | $604.48M | $11.16 | — |
News headlines (Yahoo Finance, 1h cache)
Allogene (ALLO) Q2 2026 Earnings Call Transcript
2026-08-19 20:58 · Yahoo
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
2026-08-13 17:47 · Yahoo
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
2026-08-13 15:33 · Yahoo
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ...
2026-08-13 05:01 · Yahoo
Allogene Therapeutics Q2 Earnings Call Highlights
2026-08-12 22:04 · Yahoo
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
2026-08-12 20:05 · Yahoo
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
2026-08-04 12:30 · Yahoo
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Sol
2026-07-15 12:30 · Yahoo
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions
2026-06-28 05:05 · Yahoo
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
2026-06-17 15:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.